|
1
|
Fadlallah H, El Masri J, Fakhereddine H,
Youssef J, Chemaly C, Doughan S and Abou-Kheir W: Colorectal
cancer: Recent advances in management and treatment. World J Clin
Oncol. 15:1136–1156. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morgan E, Arnold M, Gini A, Lorenzoni V,
Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N and Bray F:
Global burden of colorectal cancer in 2020 and 2040: Incidence and
mortality estimates from GLOBOCAN. Gut. 72:338–344. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pan H, Zhao Z, Deng Y, Zheng Z, Huang Y,
Huang S and Chi P: The global, regional, and national early-onset
colorectal cancer burden and trends from 1990 to 2019: Results from
the global burden of disease study 2019. BMC Public Health.
22:18962022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maida M, Dahiya DS, Shah YR, Tiwari A,
Gopakumar H, Vohra I, Khan A, Jaber F, Ramai D and Facciorusso A:
Screening and surveillance of colorectal cancer: A review of the
literature. Cancers (Basel). 16:27462024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zabaleta J, Iida T, Falcoz PE, Salah S,
Jarabo JR, Correa AM, Zampino MG, Matsui T, Cho S, Ardissone F, et
al: Individual data meta-analysis for the study of survival after
pulmonary metastasectomy in colorectal cancer patients: A history
of resected liver metastases worsens the prognosis. Eur J Surg
Oncol. 44:1006–1012. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Verwaal VJ, van Ruth S, de Bree E, van
Slooten GW, van Tinteren H, Boot H and Zoetmulder FAN: Randomized
trial of cytoreduction and hyperthermic intraperitoneal
chemotherapy versus systemic chemotherapy and palliative surgery in
patients with peritoneal carcinomatosis of colorectal cancer. J
Clin Oncol. 21:3737–3743. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cercek A, Lumish M, Sinopoli J, Weiss J,
Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M,
Sugarman R, et al: PD-1 blockade in mismatch repair-deficient,
locally advanced rectal cancer. N Engl J Med. 386:2363–2376. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chalabi M, Verschoor YL, van den Berg J,
Sikorska K, Beets G, Lent AV, Grootscholten MC, Aalbers A, Buller
N, Marsman H, et al: LBA7 Neoadjuvant immune checkpoint inhibition
in locally advanced MMR-deficient colon cancer: The NICHE-2 study.
Ann Oncol. 33(Suppl 7): S13892022. View Article : Google Scholar
|
|
10
|
Yang J, Nie J, Ma X, Wei Y, Peng Y and Wei
X: Targeting PI3K in cancer: Mechanisms and advances in clinical
trials. Mol Cancer. 18:262019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Javid H, Hashemian P, Yazdani S, Sharbaf
Mashhad A and Karimi-Shahri M: The role of heat shock proteins in
metastatic colorectal cancer: A review. J Cell Biochem.
123:1704–1735. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Golestaneh M, Firoozrai M, Javid H and
Hashemy SI: The substance P/neurokinin-1 receptor signaling pathway
mediates metastasis in human colorectal SW480 cancer cells. Mol
Biol Rep. 49:4893–4900. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aapro M, Jelkmann W, Constantinescu SN and
Leyland-Jones B: Effects of erythropoietin receptors and
erythropoiesis-stimulating agents on disease progression in cancer.
Br J Cancer. 106:1249–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
González-Perera I, Gutiérrez-Nicolás F,
Nazco-Casariego GJ, Ramos-Díaz R, Hernández-San Gil R, Pérez-Pérez
JA, González García J and González De La Fuente GA: 5-fluorouracil
toxicity in the treatment of colon cancer associated with the
genetic polymorphism 2846 A>G (rs67376798). J Oncol Pharm Pract.
23:396–398. 2017. View Article : Google Scholar
|
|
15
|
Javid H, Karimi-Shahri M, Khorramdel M,
Mashhad AS, Tabrizi AT, Sathyapalan T, Afshari AR and Sahebkar A:
Probiotics as an adjuvant for management of gastrointestinal
cancers through their anti-inflammatory effects: A mechanistic
review. Curr Med Chem. 30:390–406. 2023. View Article : Google Scholar
|
|
16
|
Ogura A, Konishi T, Cunningham C,
Garcia-Aguilar J, Iversen H, Toda S, Lee IK, Lee HX, Uehara K, Lee
P, et al: Neoadjuvant (Chemo)radiotherapy with total mesorectal
excision only is not sufficient to prevent lateral local recurrence
in enlarged nodes: Results of the multicenter lateral node study of
patients with low cT3/4 rectal cancer. J Clin Oncol. 37:33–43.
2019. View Article : Google Scholar :
|
|
17
|
Ye LY, Li YS, Ge T, Liu LC, Si JX, Yang X,
Fan WJ, Liu XZ, Zhang YN, Wang JW, et al: Engineered luminescent
oncolytic vaccinia virus activation of photodynamic-immune
combination therapy for colorectal cancer. Adv Healthc Mater.
13:e23041362024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruan Z, Chi J, Kong Y, Li C, Ruan X, Zhou
X, Chen Y, Li Y and Luo Z: Natural oncolysis of enterovirus 71 in
antitumor therapy of colorectal cancer. Adv Biol (Weinh).
7:e22003362023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Komant S, Wang J, Favis N, Alex C, Evans
DH, Noyce RS and Baldwin TA: Oncolytic vaccinia virus as a
precision cancer vaccine platform. bioRxiv. 2024.08.16.608170.
2024.
|
|
20
|
Nasar RT, Uche IK and Kousoulas KG:
Targeting cancers with oHSV-based oncolytic viral immunotherapy.
Curr Issues Mol Biol. 46:5582–5594. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren Y, Miao JM, Wang YY, Fan Z, Kong XB,
Yang L and Cheng G: Oncolytic viruses combined with immune
checkpoint therapy for colorectal cancer is a promising treatment
option. Front Immunol. 13:9617962022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang XL, Xu HW and Liu NN: Oral
microbiota: A new insight into cancer progression, diagnosis and
treatment. Phenomics. 3:535–547. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mai Z, Lin Y, Lin P, Zhao X and Cui L:
Modulating extracellular matrix stiffness: A strategic approach to
boost cancer immunotherapy. Cell Death Dis. 15:3072024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalli M, Poskus MD, Stylianopoulos T and
Zervantonakis IK: Beyond matrix stiffness: Targeting force-induced
cancer drug resistance. Trends Cancer. 9:937–954. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu
X, Zhang Z, Yang S and Xiao M: Extracellular matrix remodeling in
tumor progression and immune escape: From mechanisms to treatments.
Mol Cancer. 22:482023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmed H, Mahmud AR, Siddiquee MF, Shahriar
A, Biswas P, Shimul MEK, Ahmed SZ, Ema TI, Rahman N, Khan MA, et
al: Role of T cells in cancer immunotherapy: Opportunities and
challenges. Cancer Pathog Ther. 1:116–126. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Noro J, Vilaça-Faria H, Reis RL and
Pirraco RP: Extracellular matrix-derived materials for tissue
engineering and regenerative medicine: A journey from isolation to
characterization and application. Bioact Mater. 34:494–519.
2024.PubMed/NCBI
|
|
28
|
Sorokin M, Zolotovskaia M, Nikitin D,
Suntsova M, Poddubskaya E, Glusker A, Garazha A, Moisseev A, Li X,
Sekacheva M, et al: Personalized targeted therapy prescription in
colorectal cancer using algorithmic analysis of RNA sequencing
data. BMC Cancer. 22:11132022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu H, Zhang S, Cai L, Duan H, Li Y, Yang
J, Wang Y and Liu B, Dong S, Fang Z and Liu B: A novel cocktail
therapy based on quintuplet combination of oncolytic herpes simplex
virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF,
PD1v, and IL-7 x CCL19 results in enhanced antitumor efficacy.
Virol J. 19:742022. View Article : Google Scholar
|
|
30
|
Ribas A, Dummer R, Puzanov I, VanderWalde
A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J,
Fernandez E, et al: Oncolytic virotherapy promotes intratumoral T
cell infiltration and improves Anti-PD-1 immunotherapy. Cell.
170:1109–1119.e10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garcia-Carbonero R, Salazar R, Duran I,
Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L,
Beadle J, et al: Phase 1 study of intravenous administration of the
chimeric adenovirus enadenotucirev in patients undergoing primary
tumor resection. J Immunother Cancer. 5:712017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Ren Y, Wang F, Tu X, Tong Z, Liu
L, Zheng Y, Zhao P, Cheng J, Li J, et al: The long-term
effectiveness and mechanism of oncolytic virotherapy combined with
anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Ther.
31:1412–1426. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Berkey SE, Thorne SH and Bartlett DL:
Oncolytic virotherapy and the tumor microenvironment. Tumor Immune
Microenvironment in Cancer Progression and Cancer Therapy. Kalinski
P: Springer International Publishing; Cham: pp. 157–172. 2017
|
|
34
|
Cai L, Chen A and Tang D: A new strategy
for immunotherapy of microsatellite-stable (MSS)-type advanced
colorectal cancer: Multi-pathway combination therapy with
PD-1/PD-L1 inhibitors. Immunology. 173:209–226. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hajeri PB, Sharma NS and Yamamoto M:
Oncolytic adenoviruses: Strategies for improved targeting and
specificity. Cancers (Basel). 12:15042020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Samson A, Smolenschi C, Cassier P, Patel
JV, Hammond C, Kurzawa M, Sainte-Croix S, West E, Sadoun A and
Bendjama K: Abstract CT190: Oncolytic virus TG6002 safety and
activity after intrahepatic artery administration in patients with
liver-dominant metastatic colorectal cancer. Cancer Res. 83(8
Suppl): CT1902023. View Article : Google Scholar
|
|
37
|
Lavilla-Alonso S, Bauerschmitz G,
Abo-Ramadan U, Halavaara J, Escutenaire S, Diaconu I, Tatlisumak T,
Kanerva A, Hemminki A and Pesonen S: Adenoviruses with an αvβ
integrin targeting moiety in the fiber shaft or the HI-loop
increase tumor specificity without compromising antitumor efficacy
in magnetic resonance imaging of colorectal cancer metastases. J
Transl Med. 8:802010. View Article : Google Scholar
|
|
38
|
Naumenko VA, Stepanenko AA, Lipatova AV,
Vishnevskiy DA and Chekhonin VP: Infection of non-cancer cells: A
barrier or support for oncolytic virotherapy? Mol Ther Oncolytics.
24:663–682. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen G, Wu K, Li H, Xia D and He T: Role
of hypoxia in the tumor microenvironment and targeted therapy.
Front Oncol. 12:9616372022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kingsak M, Meethong T, Jongkhumkrong J,
Cai L and Wang Q: Therapeutic potential of oncolytic viruses in the
era of precision oncology. Biomater Transl. 4:67–84. 2023.
|
|
41
|
Peng Z, Kalim M and Lu Y: Improving
systemic delivery of oncolytic virus by cellular carriers. Cancer
Biol Med. 21:1104–1119. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen L, Zuo M, Zhou Q and Wang Y:
Oncolytic virotherapy in cancer treatment: Challenges and
optimization prospects. Front Immunol. 14:13088902023. View Article : Google Scholar
|
|
43
|
Crupi MJF, Taha Z, Janssen TJA, Petryk J,
Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, et
al: Oncolytic virus driven T-cell-based combination immunotherapy
platform for colorectal cancer. Front Immunol. 13:10292692022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen X, Wang G, Qin L, Hu B and Li J:
Intestinal microbiota modulates the antitumor effect of oncolytic
virus vaccines in colorectal cancer. Dig Dis Sci. 69:1228–1241.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kontermann RE, Ungerechts G and Nettelbeck
DM: Viro-antibody therapy: Engineering oncolytic viruses for
genetic delivery of diverse antibody-based biotherapeutics. MAbs.
13:19824472021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zheng M, Huang J, Tong A and Yang H:
Oncolytic viruses for cancer therapy: Barriers and recent advances.
Mol Ther Oncolytics. 15:234–247. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu J, Ma J, Huang M, Deng H and Shi G:
Emerging delivery strategy for oncolytic virotherapy. Mol Ther
Oncol. 32:2008092024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Song Z, Tao Y, Liu Y and Li J: Advances in
delivery systems for CRISPR/Cas-mediated cancer treatment: A focus
on viral vectors and extracellular vesicles. Front Immunol.
15:14444372024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mainenti PP, Stanzione A, Guarino S, Romeo
V, Ugga L, Romano F, Storto G, Maurea S and Brunetti A: Colorectal
cancer: Parametric evaluation of morphological, functional and
molecular tomographic imaging. World J Gastroenterol. 25:5233–5256.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang T, Jiang S, Zhang L, Liu Y, Zheng H,
Zhao H, Du S, Xu Y and Lu X: A bibliometric analysis of oncolytic
virotherapy combined with immunotherapy. Hum Vaccin Immunother.
20:24066212024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chai C, Zhang J, Zhou Y, Yin H, Zhang F,
Diao Y, Zan X, Ma Y, Wang Y, Wu Y and Wang W: The effects of
oncolytic pseudorabies virus vaccine strain inhibited the growth of
colorectal cancer HCT-8 cells in vitro and in vivo. Animals
(Basel). 12:24162022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Girod M, Geisler A, Hinze L, Elsner L,
Dieringer B, Beling A, Kurreck J and Fechner H: Combination of
FOLFOXIRI drugs with oncolytic coxsackie B3 virus PD-H
synergistically induces oncolysis in the refractory colorectal
cancer cell line Colo320. Int J Mol Sci. 25:56182024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Enow JA, Sheikh HI and Rahman MM: Tumor
tropism of DNA viruses for oncolytic virotherapy. Viruses.
15:22622023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tian Y, Xie D and Yang L: Engineering
strategies to enhance oncolytic viruses in cancer immunotherapy.
Signal Transduct Target Ther. 7:1172022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin D, Shen Y and Liang T: Oncolytic
virotherapy: Basic principles, recent advances and future
directions. Signal Transduct Target Ther. 8:1562023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Robilotti E, Zeitouni NC and Orloff M:
Biosafety and biohazard considerations of HSV-1-based oncolytic
viral immunotherapy. Front Mol Biosci. 10:11783822023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shalhout SZ, Miller DM, Emerick KS and
Kaufman HL: Therapy with oncolytic viruses: progress and
challenges. Nat Rev Clin Oncol. 20:160–177. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Alkayyal AA, Darwish M, Ajina R, Alabbas
SY, Alotaibi MA, Alsofyani A, Bokhamseen M, Hakami M, Albaradie OA,
Moglan AM, et al: Repurposing the oncolytic virus VSV∆51M as a
COVID-19 vaccine. Front Bioeng Biotechnol. 11:11508922023.
View Article : Google Scholar
|
|
59
|
Ranki T, Särkioja M, Hakkarainen T, von
Smitten K, Kanerva A and Hemminki A: Systemic efficacy of oncolytic
adenoviruses in imagable orthotopic models of hormone refractory
metastatic breast cancer. Int J Cancer. 121:165–174. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Niemann J and Kühnel F: Oncolytic viruses:
Adenoviruses. Virus Genes. 53:700–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bolyard C, Yoo JY, Wang PY, Saini U, Rath
KS, Cripe TP, Zhang J, Selvendiran K and Kaur B: Doxorubicin
synergizes with 34.5ENVE to enhance antitumor efficacy against
metastatic ovarian cancer. Clin Cancer Res. 20:6479–6494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Meisen WH, Dubin S, Sizemore ST,
Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder
JB, Powell K, et al: Changes in BAI1 and nestin expression are
prognostic indicators for survival and metastases in breast cancer
and provide opportunities for dual targeted therapies. Mol Cancer
Ther. 14:307–314. 2015. View Article : Google Scholar :
|
|
63
|
Medrano RFV, Hunger A, Mendonça SA,
Barbuto JAM and Strauss BE: Immunomodulatory and antitumor effects
of type I interferons and their application in cancer therapy.
Oncotarget. 8:71249–71284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hirvinen M, Rajecki M, Kapanen M,
Parviainen S, Rouvinen-Lagerström N, Diaconu I, Nokisalmi P,
Tenhunen M, Hemminki A and Cerullo V: Immunological effects of a
tumor necrosis factor alpha-armed oncolytic adenovirus. Hum Gene
Ther. 26:134–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang B, Wang X and Cheng P: Remodeling of
tumor immune microenvironment by oncolytic viruses. Front Oncol.
10:5613722021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hazafa A, Mumtaz M, Farooq MF, Bilal S,
Chaudhry SN, Firdous M, Naeem H, Ullah MO, Yameen M, Mukhtiar MS
and Zafar F: CRISPR/Cas9: A powerful genome editing technique for
the treatment of cancer cells with present challenges and future
directions. Life Sci. 263:1185252020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang N, Li J, Yu J, Wan Y, Zhang C, Zhang
H and Cao Y: Construction of an IL12 and CXCL11 armed oncolytic
herpes simplex virus using the CRISPR/Cas9 system for colon cancer
treatment. Virus Res. 323:1989792023. View Article : Google Scholar :
|
|
68
|
Wang L, Chen Y, Liu X, Li Z and Dai X: The
application of CRISPR/Cas9 technology for cancer immunotherapy:
Current status and problems. Front Oncol. 11:7049992022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ilkow CS and Bell JC: Optimizing oncolytic
virus design: A 'Swiss army knife' approach to create a
systemically delivered therapeutic. Signal Transduct Target Ther.
9:822024. View Article : Google Scholar
|
|
70
|
Xiao B, Ying C, Chen Y, Huang F, Wang B,
Fang H, Guo W, Liu T, Zhou X, Huang B, et al: Doxorubicin
hydrochloride enhanced antitumour effect of CEA-regulated oncolytic
virotherapy in live cancer cells and a mouse model. J Cell Mol Med.
24:13431–13439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Xiao B, Zhang L, Liu H, Fang H, Wang C,
Huang B, Liu X, Zhou X and Wang Y: Oncolytic adenovirus cd55-smad4
suppresses cell proliferation, metastasis, and tumor stemness in
colorectal cancer by regulating wnt/β-catenin signaling pathway.
Biomedicines. 8:5932020. View Article : Google Scholar
|
|
72
|
Zhang Y, Ye M, Huang F, Wang S, Wang H,
Mou X and Wang Y: Oncolytic adenovirus expressing ST13 increases
antitumor effect of tumor necrosis factor-related
apoptosis-inducing ligand against pancreatic ductal adenocarcinoma.
Hum Gene Ther. 31:891–903. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Luo Q, Song H, Deng X, Li J, Jian W, Zhao
J, Zheng X, Basnet S, Ge H, Daniel T, et al: A triple-regulated
oncolytic adenovirus carrying MicroRNA-143 exhibits potent
antitumor efficacy in colorectal cancer. Mol Ther Oncolytics.
16:219–229. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Toropko M, Chuvpilo S and Karabelsky A:
miRNA-mediated mechanisms in the generation of effective and safe
oncolytic viruses. Pharmaceutics. 16:9862024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yu B, Kang J, Lei H, Li Z, Yang H and
Zhang M: Immunotherapy for colorectal cancer. Front Immunol.
15:14333152024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhao JL, Lin BL, Luo C, Yi YL, Huang P,
Chen Y, Zhao S, Huang ZJ, Ma XY and Huang L: Challenges and
strategies toward oncolytic virotherapy for leptomeningeal
metastasis. J Transl Med. 22:10002024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Oronsky B, Gastman B, Conley AP, Reid C,
Caroen S and Reid T: Oncolytic adenoviruses: The cold war against
cancer finally turns hot. Cancers (Basel). 14:47012022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yin L, Zhao C, Han J, Li Z, Zhen Y, Xiao
R, Xu Z and Sun Y: Antitumor effects of oncolytic herpes simplex
virus type 2 against colorectal cancer in vitro and in vivo. Ther
Clin Risk Manag. 13:117–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Gong J, Sachdev E, Mita AC and Mita MM:
Clinical development of reovirus for cancer therapy: An oncolytic
virus with immune-mediated antitumor activity. World J Methodol.
6:25–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li M, Zhang M, Ye Q, Liu Y and Qian W:
Preclinical and clinical trials of oncolytic vaccinia virus in
cancer immunotherapy: A comprehensive review. Cancer Biol Med.
20:646–661. 2023.PubMed/NCBI
|
|
81
|
Davis D and Lahiri SS: Application of
oncolytic viruses for cure of colorectal cancer. Cancer Res J.
3:76–93. 2015. View Article : Google Scholar
|
|
82
|
Kana SI and Essani K: Immuno-oncolytic
viruses: Emerging options in the treatment of colorectal cancer.
Mol Diagn Ther. 25:301–313. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Larocca CJ, Wilber S, Jensen E, Steer C
and Davydova J: 428 Development of an Oncolytic Adenovirus to Treat
Metastatic Colorectal Cancer. J Clin Transl Sci. 7(Suppl 1):
1282023. View Article : Google Scholar :
|
|
84
|
Huang L, Zhao H, Shan M, Chen H, Xu B, He
Y, Zhao Y, Liu Z, Chen J and Xu Q: Oncolytic adenovirus H101
ameliorate the efficacy of anti-PD-1 monotherapy in colorectal
cancer. Cancer Med. 11:4575–4587. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Li YS, Ye LY, Luo YX, Zheng WJ, Si JX,
Yang X, Zhang YN, Wang SB, Zou H, Jin KT, et al: Tumor-targeted
delivery of copper-manganese biomineralized oncolytic adenovirus
for colorectal cancer immunotherapy. Acta Biomater. 179:243–255.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Scanlan H, Coffman Z, Bettencourt J,
Shipley T and Bramblett DE: Herpes simplex virus 1 as an oncolytic
viral therapy for refractory cancers. Front Oncol. 12:9400192022.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ferrucci PF, Pala L, Conforti F and
Cocorocchio E: Talimogene laherparepvec (T-VEC): An intralesional
cancer immunotherapy for advanced melanoma. Cancers (Basel).
13:13832021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Park SH, Breitbach CJ, Lee J, Park JO, Lim
HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, et al:
Phase 1b trial of biweekly intravenous pexa-Vec (JX-594), an
oncolytic and immunotherapeutic vaccinia virus in colorectal
cancer. Mol Ther. 23:1532–1540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Harrop R, Drury N, Shingler W, Chikoti P,
Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls
J, et al: Vaccination of colorectal cancer patients with modified
vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given
alongside chemotherapy induces potent immune responses. Clin Cancer
Res. 13:4487–4494. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Koch MS, Lawler SE and Chiocca EA: HSV-1
oncolytic viruses from bench to bedside: An overview of current
clinical trials. Cancers (Basel). 12:35142020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Snook AE, Baybutt TR, Xiang B, Abraham TS,
Flickinger JC Jr, Hyslop T, Zhan T, Kraft WK, Sato T and Waldman
SA: Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced
T-cell responses in colon cancer patients. J Immunother Cancer.
7:1042019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Balint JP, Gabitzsch ES, Rice A, Latchman
Y, Xu Y, Messerschmidt GL, Chaudhry A, Morse MA and Jones FR:
Extended evaluation of a phase 1/2 trial on dosing, safety,
immunogenicity, and overall survival after immunizations with an
advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage
colorectal cancer. Cancer Immunol Immunother. 64:977–987. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Gögenur M, Balsevicius L, Bulut M, Colak
N, Justesen TF, Fiehn AK, Jensen MB, Høst-Rasmussen K, Cappelen B,
Gaggar S, et al: Neoadjuvant intratumoral influenza vaccine
treatment in patients with proficient mismatch repair colorectal
cancer leads to increased tumor infiltration of CD8+ T cells and
upregulation of PD-L1: A phase 1/2 clinical trial. J Immunother
Cancer. 11:e0067742023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jooss K, Ertl HC and Wilson JM: Cytotoxic
T-lymphocyte target proteins and their major histocompatibility
complex class I restriction in response to adenovirus vectors
delivered to mouse liver. J Virol. 72:2945–2954. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Xue Y, Ruan Y, Wang Y, Xiao P and Xu J:
Signaling pathways in liver cancer: Pathogenesis and targeted
therapy. Mol Biomed. 5:202024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Calistri D, Rengucci C, Seymour I,
Lattuneddu A, Polifemo AM, Monti F, Saragoni L and Amadori D:
Mutation analysis of p53, K-ras, and BRAF genes in colorectal
cancer progression. J Cell Physiol. 204:484–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Fodde R: The APC gene in colorectal
cancer. Eur J Cancer. 38:867–871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mehrvarz Sarshekeh A, Advani S, Overman
MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E,
Manuel S, et al: Association of SMAD4 mutation with patient
demographics, tumor characteristics, and clinical outcomes in
colorectal cancer. PLoS One. 12:e01733452017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chung Y, Wi YC, Kim Y, Bang SS, Yang JH,
Jang K, Min KW and Paik SS: The Smad4/PTEN expression pattern
predicts clinical outcomes in colorectal adenocarcinoma. J Pathol
Transl Med. 52:37–44. 2018. View Article : Google Scholar :
|
|
100
|
Vaughn CP, ZoBell SD, Furtado LV, Baker CL
and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in
colorectal cancer. Genes Chromosomes Cancer. 50:307–312. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Überall I, Kolář Z, Trojanec R, Berkovcová
J and Hajdúch M: The status and role of ErbB receptors in human
cancer. Exp Mol Pathol. 84:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kerk SA, Papagiannakopoulos T, Shah YM and
Lyssiotis CA: Metabolic networks in mutant KRAS-driven tumours:
Tissue specificities and the microenvironment. Nat Rev Cancer.
21:510–525. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Schmitz KJ, Ademi C, Bertram S, Schmid KW
and Baba HA: Prognostic relevance of autophagy-related markers LC3,
p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients
with respect to KRAS mutational status. World J Surg Oncol.
14:1892016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Jiffry J, Thavornwatanayong T, Rao D,
Fogel EJ, Saytoo D, Nahata R, Guzik H, Chaudhary I, Augustine T,
Goel S and Maitra R: Oncolytic reovirus (pelareorep) induces
autophagy in KRAS-mutated colorectal cancer. Clin Cancer Res.
27:865–876. 2021. View Article : Google Scholar :
|
|
105
|
Goel S, Ocean AJ, Parakrama RY, Ghalib MH,
Chaudhary I, Shah U, Viswanathan S, Kharkwal H, Coffey M and Maitra
R: Elucidation of pelareorep pharmacodynamics in A phase I trial in
patients with KRAS-mutated colorectal cancer. Mol Cancer Ther.
19:1148–1156. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Su Z, El Hage M and Linnebacher M:
Mutation patterns in colorectal cancer and their relationship with
prognosis. Heliyon. 10:e365502024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sommariva S, Caviglia G, Ravera S,
Frassoni F, Benvenuto F, Tortolina L, Castagnino N, Parodi S and
Piana M: Computational quantification of global effects induced by
mutations and drugs in signaling networks of colorectal cancer
cells. Sci Rep. 11:196022021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zeng M, Zhang W, Li Y and Yu L: Harnessing
adenovirus in cancer immunotherapy: Evoking cellular immunity and
targeting delivery in cell-specific manner. Biomark Res. 12:362024.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Liu CC, Liu JH, Wu SC, Yen CC, Chen WS and
Tsai YC: A novel E1B-55kD-deleted oncolytic adenovirus carrying
mutant KRAS-regulated hdm2 transgene exerts specific antitumor
efficacy on colorectal cancer cells. Mol Cancer Ther. 9:450–460.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Planchard D, Besse B, Groen HJM, Souquet
PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, et
al: Dabrafenib plus trametinib in patients with previously treated
BRAF(V600E)-mutant metastatic non-small cell lung cancer: An
open-label, multicentre phase 2 trial. Lancet Oncol. 17:984–993.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kopetz S, Grothey A, Yaeger R, Van Cutsem
E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS,
et al: Encorafenib, binimetinib, and cetuximab in BRAF
V600E-mutated colorectal cancer. N Engl J Med. 381:1632–1643. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kopetz S, Murphy DA, Pu J, Ciardiello F,
Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, et
al: Molecular profiling of BRAF-V600E-mutant metastatic colorectal
cancer in the phase 3 BEACON CRC trial. Nat Med. 30:3261–3271.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Ivanova M, Venetis K, Guerini-Rocco E,
Bottiglieri L, Mastropasqua MG, Garrone O, Fusco N and Ghidini M:
HER2 in metastatic colorectal cancer: Pathology, somatic
alterations, and perspectives for novel therapeutic schemes. Life
(Basel). 12:14032022.PubMed/NCBI
|
|
114
|
Yonesaka K, Zejnullahu K, Okamoto I, Satoh
T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda
M, et al: Activation of ERBB2 signaling causes resistance to the
EGFR-directed therapeutic antibody cetuximab. Sci Transl Med.
3:99ra86. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Takegawa N and Yonesaka K: HER2 as an
emerging oncotarget for colorectal cancer treatment after failure
of anti-epidermal growth factor receptor therapy. Clin Colorectal
Cancer. 16:247–251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Liu H, Zhou D, Liu D, Xu X, Zhang K, Hu R,
Xiong P, Wang C, Zeng X, Wang L and Zhang S: Synergistic antitumor
activity between HER2 antibody-drug conjugate and chemotherapy for
treating advanced colorectal cancer. Cell Death Dis. 15:1872024.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li K, Luo H, Huang L, Luo H and Zhu X:
Microsatellite instability: A review of what the oncologist should
know. Cancer Cell Int. 20:162020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Xiao B, Qin Y, Ying C, Ma B, Wang B, Long
F, Wang R, Fang L and Wang Y: Combination of oncolytic adenovirus
and luteolin exerts synergistic antitumor effects in colorectal
cancer cells and a mouse model. Mol Med Rep. 16:9375–9382. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Calu V, Ionescu A, Stanca L, Geicu OI,
Iordache F, Pisoschi AM, Serban AI and Bilteanu L: Key biomarkers
within the colorectal cancer related inflammatory microenvironment.
Sci Rep. 11:79402021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Mao C, Yang ZY, Hu XF, Chen Q and Tang JL:
PIK3CA exon 20 mutations as a potential biomarker for resistance to
anti-EGFR monoclonal antibodies in KRAS wild-type metastatic
colorectal cancer: A systematic review and meta-analysis. Ann
Oncol. 23:1518–1525. 2012. View Article : Google Scholar
|
|
122
|
Wu X, Yan H, Qiu M, Qu X, Wang J, Xu S,
Zheng Y, Ge M, Yan L and Liang L: Comprehensive characterization of
tumor microenvironment in colorectal cancer via molecular analysis.
Elife. 12:e860322023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hirata E and Sahai E: Tumor
microenvironment and differential responses to therapy. Cold Spring
Harb Perspect Med. 7:a0267812017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Jia Q, Wang A, Yuan Y, Zhu B and Long H:
Heterogeneity of the tumor immune microenvironment and its clinical
relevance. Exp Hematol Oncol. 11:242022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zhang L, Yu X, Zheng L, Zhang Y, Li Y,
Fang Q, Gao R, Kang B, Zhang Q, Huang JY, et al: Lineage tracking
reveals dynamic relationships of T cells in colorectal cancer.
Nature. 564:268–272. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Karlsson S and Nyström H: The
extracellular matrix in colorectal cancer and its metastatic
settling-Alterations and biological implications. Crit Rev Oncol
Hematol. 175:1037122022. View Article : Google Scholar
|
|
127
|
Becht E, de Reyniès A, Giraldo NA, Pilati
C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P
and Fridman WH: Immune and stromal classification of colorectal
cancer is associated with molecular subtypes and relevant for
precision immunotherapy. Clin Cancer Res. 22:4057–4066. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Jin MZ and Jin WL: The updated landscape
of tumor microenvironment and drug repurposing. Signal Transduct
Target Ther. 5:1662020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ohta A, Kini R, Ohta A, Subramanian M,
Madasu M and Sitkovsky M: The development and immunosuppressive
functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under
influence of the adenosine-A2A adenosine receptor pathway. Front
Immunol. 3:1902012. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Schmidt A, Oberle N and Krammer PH:
Molecular mechanisms of treg-mediated T cell suppression. Front
Immunol. 3:512012. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ghiringhelli F, Puig PE, Roux S, Roux S,
Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B
and Zitvogel L: Tumor cells convert immature myeloid dendritic
cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T
cell proliferation. J Exp Med. 202:919–929. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Morello S, Pinto A, Blandizzi C and
Antonioli L: Myeloid cells in the tumor microenvironment: Role of
adenosine. Oncoimmunology. 5:e11085152016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Aristin Revilla S, Kranenburg O and Coffer
PJ: Colorectal cancer-infiltrating regulatory T cells: Functional
heterogeneity, metabolic adaptation, and therapeutic targeting.
Front Immunol. 13:9035642022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Hong J, Chen X, Chen L, Wang Y, Huang B
and Fang H: Clinical value of combined detection of serum sTim-3
and CEA or CA19-9 for postoperative recurrence of colorectal cancer
diagnosis. Cancer Manag Res. 15:563–572. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
He X and Xu C: Immune checkpoint signaling
and cancer immunotherapy. Cell Res. 30:660–669. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Dong H, Li M, Yang C, Wei W, He X, Cheng G
and Wang S: Combination therapy with oncolytic viruses and immune
checkpoint inhibitors in head and neck squamous cell carcinomas: An
approach of complementary advantages. Cancer Cell Int. 23:12023.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Song D, Hou S, Ma N, Yan B and Gao J:
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint
inhibitors in the treatment of advanced colorectal cancer: A
systematic review and meta-analysis. Front Immunol. 15:14853032024.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Chen EX, Jonker DJ, Loree JM, Kennecke HF,
Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, et al:
Effect of combined immune checkpoint inhibition vs best supportive
care alone in patients with advanced colorectal cancer: The
Canadian cancer trials group CO.26 study. JAMA Oncol. 6:831–838.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Thibaudin M, Fumet JD, Chibaudel B,
Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J,
Limagne E, et al: First-line durvalumab and tremelimumab with
chemotherapy in RAS-mutated metastatic colorectal cancer: a phase
1b/2 trial. Nat Med. 29:2087–2098. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Shi T, Song X, Wang Y, Liu F and Wei J:
Combining oncolytic viruses with cancer immunotherapy: Establishing
a new generation of cancer treatment. Front Immunol. 11:6832020.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Xu H, Russell SN, Steiner K, O'Neill E and
Jones KI: Targeting PI3K-gamma in myeloid driven tumour immune
suppression: A systematic review and meta-analysis of the
preclinical literature. Cancer Immunol Immunother. 73:2042024.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Arai H, Battaglin F, Wang J, Lo JH, Soni
S, Zhang W and Lenz HJ: Molecular insight of regorafenib treatment
for colorectal cancer. Cancer Treat Rev. 81:1019122019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Zhou J, Ji Q and Li Q: Resistance to
anti-EGFR therapies in metastatic colorectal cancer: Underlying
mechanisms and reversal strategies. J Exp Clin Cancer Res.
40:3282021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Leiphrakpam PD and Are C: PI3K/Akt/mTOR
signaling pathway as a target for colorectal cancer treatment. Int
J Mol Sci. 25:31782024. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Stefani C, Miricescu D, Stanescu-Spinu II,
Nica RI, Greabu M, Totan AR and Jinga M: Growth factors,
PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer
pathogenesis: Where are we now? Int J Mol Sci. 22:102602021.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab versus chemotherapy for microsatellite
instability-high or mismatch repair-deficient metastatic colorectal
cancer (KEYNOTE-177): Final analysis of a randomised, open-label,
phase 3 study. Lancet Oncol. 23:659–670. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kalyan A, Kircher S, Shah H, Mulcahy M and
Benson A: Updates on immunotherapy for colorectal cancer. J
Gastrointest Oncol. 9:160–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Huo G, Liu W, Zhang S and Chen P: Efficacy
of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on
clinical characteristics: a meta-analysis. Immunotherapy.
15:189–207. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Shi Y, Wang X, Meng Y, Ma J, Zhang Q, Shao
G, Wang L, Cheng X, Hong X, Wang Y, et al: A novel mechanism of
endoplasmic reticulum stress- and c-Myc-degradation-mediated
therapeutic benefits of antineurokinin-1 receptor drugs in
colorectal cancer. Adv Sci (Weinh). 8:e21019362021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Benboubker V, Ramzy GM, Jacobs S and
Nowak-Sliwinska P: Challenges in validation of combination
treatment strategies for CRC using patient-derived organoids. J Exp
Clin Cancer Res. 43:2592024. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Sillo TO, Beggs AD, Morton DG and
Middleton G: Mechanisms of immunogenicity in colorectal cancer. Br
J Surg. 106:1283–1297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Hu Z, Li Y, Yang J, Liu J, Zhou H, Sun C,
Tian C, Zhu C, Shao M, Wang S, et al: Improved antitumor
effectiveness of oncolytic HSV-1 viruses engineered with
IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets
colon cancer. Sci Rep. 14:236712024. View Article : Google Scholar
|
|
156
|
Bommareddy PK, Shettigar M and Kaufman HL:
Integrating oncolytic viruses in combination cancer immunotherapy.
Nat Rev Immunol. 18:498–513. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Liu Z, Ravindranathan R, Kalinski P, Guo
ZS and Bartlett DL: Rational combination of oncolytic vaccinia
virus and PD-L1 blockade works synergistically to enhance
therapeutic efficacy. Nat Commun. 8:147542017. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Xie X, Lv J, Zhu W, Tian C, Li J, Liu J,
Zhou H, Sun C, Hu Z and Li X: The combination therapy of oncolytic
HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor
efficacy. Transl Oncol. 15:1012872022. View Article : Google Scholar
|
|
159
|
Jung I, Shin S, Baek MC and Yea K:
Modification of immune cell-derived exosomes for enhanced cancer
immunotherapy: Current advances and therapeutic applications. Exp
Mol Med. 56:19–31. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Fan T, Zhang M, Yang J, Zhu Z, Cao W and
Dong C: Therapeutic cancer vaccines: Advancements, challenges, and
prospects. Signal Transduct Target Ther. 8:4502023. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Senzer NN, Kaufman H, Amatruda T,
Nemunaitis M, Daniels GA, Glaspy J, Goldsweig H, Coffin RS and
Nemunaitis J: Phase II clinical trial with a second generation,
GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic
melanoma. J Clin Oncol. 27(15 Suppl): S90352009. View Article : Google Scholar
|
|
162
|
Ott PA and Hodi FS: Talimogene
laherparepvec for the treatment of advanced melanoma. Clin Cancer
Res. 22:3127–3131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Ylösmäki E, Ylösmäki L, Fusciello M,
Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki
T, et al: Characterization of a novel OX40 ligand and CD40
ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer
vaccine platform. Mol Ther Oncolytics. 20:459–469. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Huang Q, Cai WQ, Han ZW, Wang MY, Zhou Y,
Cheng JT, Zhang Y, Wang YY, Xin Q, Wang XW, et al: Bispecific T
cell engagers and their synergistic tumor immunotherapy with
oncolytic viruses. Am J Cancer Res. 11:2430–2455. 2021.PubMed/NCBI
|
|
165
|
Guo ZS, Lotze MT, Zhu Z, Storkus WJ and
Song XT: Bi- and tri-specific T cell engager-armed oncolytic
viruses: Next-generation cancer immunotherapy. Biomedicines.
8:2042020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Jiang J, Li J, Zhou X, Zhao X, Huang B and
Qin Y: Exosomes regulate the epithelial-mesenchymal transition in
cancer. Front Oncol. 12:8649802022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Xiang Z, Hua M, Hao Z, Biao H, Zhu C, Zhai
G and Wu J: The roles of mesenchymal stem cells in gastrointestinal
cancers. Front Immunol. 13:8440012022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Rosenberg SA, Yang JC, Sherry RM, Kammula
US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF,
Wunderlich JR, et al: Durable complete responses in heavily
pretreated patients with metastatic melanoma using T-cell transfer
immunotherapy. Clin Cancer Res. 17:4550–4557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Nguyen HM, Bommareddy PK, Silk AW and Saha
D: Optimal timing of PD-1 blockade in combination with oncolytic
virus therapy. Semin Cancer Biol. 86:971–980. 2022. View Article : Google Scholar
|
|
170
|
Pol J, Kroemer G and Galluzzi L: First
oncolytic virus approved for melanoma immunotherapy.
Oncoimmunology. 5:e11156412015. View Article : Google Scholar
|
|
171
|
Overman MJ, Ernstoff MS and Morse MA:
Where we stand with immunotherapy in colorectal cancer: deficient
mismatch repair, proficient mismatch repair, and toxicity
management. Am Soc Clin Oncol Educ Book. 38:239–247. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Creasy JM, Sadot E, Koerkamp BG, Chou JF,
Gonen M, Kemeny NE, Balachandran VP, Kingham TP, DeMatteo RP, Allen
PJ, et al: Actual 10-year survival after hepatic resection of
colorectal liver metastases: What factors preclude cure? Surgery.
163:1238–1244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Yu J, Green MD, Li S, Sun Y, Journey SN,
Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al: Liver
metastasis restrains immunotherapy efficacy via macrophage-mediated
T cell elimination. Nat Med. 27:152–164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Garg P, Pareek S, Kulkarni P, Horne D,
Salgia R and Singhal SS: Next-generation immunotherapy: Advancing
clinical applications in cancer treatment. J Clin Med. 13:65372024.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Jin KT, Du WL, Liu YY, Lan HR, Si JX and
Mou XZ: Oncolytic virotherapy in solid tumors: The challenges and
achievements. Cancers (Basel). 13:5882021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Chen Q, Zhang H, Wu M, Wang Q, Luo L, Ma
H, Zhang X and He S: Discovery of a potent hedgehog pathway
inhibitor capable of activating caspase8-dependent apoptosis. J
Pharmacol Sci. 137:256–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Albring KF, Weidemüller J, Mittag S,
Weiske J, Friedrich K, Geroni MC, Lombardi P and Huber O: Berberine
acts as a natural inhibitor of Wnt/β-catenin
signaling-identification of more active 13-arylalkyl derivatives.
Biofactors. 39:652–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
García-Foncillas J, Sunakawa Y, Aderka D,
Wainberg Z, Ronga P, Witzler P and Stintzing S: Distinguishing
features of cetuximab and panitumumab in colorectal cancer and
other solid tumors. Front Oncol. 9:8492019. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Xie YH, Chen YX and Fang JY: Comprehensive
review of targeted therapy for colorectal cancer. Signal Transduct
Target Ther. 5:222020. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Wang D, Zhang H, Xiang T and Wang G:
Clinical application of adaptive immune therapy in MSS colorectal
cancer patients. Front Immunol. 12:7623412021. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Fukuoka S, Hara H, Takahashi N, Kojima T,
Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et
al: Regorafenib plus nivolumab in patients with advanced gastric or
colorectal cancer: An open-label, dose-escalation, and
dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol.
38:2053–2061. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Qin Y, Ma FY, Zhang Z, Zhao CH and Huang
B: Vascular endothelial growth factor pathway's influence on
bevacizumab efficacy in metastatic colorectal cancer treatment.
World J Gastrointest Oncol. 16:4514–4517. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Tilgase A, Olmane E, Nazarovs J, Brokāne
L, Erdmanis R, Rasa A and Alberts P: Multimodality treatment of a
colorectal cancer stage IV patient with FOLFOX-4, bevacizumab,
rigvir oncolytic virus, and surgery. Case Rep Gastroenterol.
12:457–465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Wu Z, Ichinose T, Naoe Y, Matsumura S,
Villalobos IB, Eissa IR, Yamada S, Miyajima N, Morimoto D, Mukoyama
N, et al: Combination of cetuximab and oncolytic virus canerpaturev
synergistically inhibits human colorectal cancer growth. Mol Ther
Oncolytics. 13:107–115. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Van Cutsem E, Tabernero J, Lakomy R,
Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko
V, Ferry D, et al: Addition of aflibercept to fluorouracil,
leucovorin, and irinotecan improves survival in a phase III
randomized trial in patients with metastatic colorectal cancer
previously treated with an oxaliplatin-based regimen. J Clin Oncol.
30:3499–3506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Holch JW, Ricard I, Stintzing S, Modest DP
and Heinemann V: The relevance of primary tumour location in
patients with metastatic colorectal cancer: A meta-analysis of
first-line clinical trials. Eur J Cancer. 70:87–98. 2017.
View Article : Google Scholar
|
|
188
|
Schmoll HJ, Tabernero J, Maroun J, de
Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K and
Haller DG: Capecitabine plus oxaliplatin compared with
fluorouracil/folinic acid as adjuvant therapy for stage iii colon
cancer: Final results of the NO16968 randomized controlled phase
III trial. J Clin Oncol. 33:3733–3740. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Lenz HJ, Ou FS, Venook AP, Hochster HS,
Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD,
Zemla T, et al: Impact of consensus molecular subtype on survival
in patients with metastatic colorectal cancer: Results from
CALGB/SWOG 80405 (alliance). J Clin Oncol. 37:1876–1885. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Dienstmann R, Vermeulen L, Guinney J,
Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes
and the evolution of precision medicine in colorectal cancer. Nat
Rev Cancer. 17:79–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Westphalen CB, Martins-Branco D, Beal JR,
Cardone C, Coleman N, Schram AM, Halabi S, Michiels S, Yap C, André
F, et al: The ESMO tumour-agnostic classifier and screener
(ETAC-S): A tool for assessing tumour-agnostic potential of
molecularly guided therapies and for steering drug development. Ann
Oncol. 35:936–953. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
McKean WB, Moser JC, Rimm D and
Hu-Lieskovan S: Biomarkers in precision cancer immunotherapy:
Promise and challenges. Am Soc Clin Oncol Educ Book. 40:e275–e291.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Steuerwald NM, Morris S, Nguyen DG and
Patel JN: Understanding the biology and testing techniques for
pharmacogenomics in oncology: A practical guide for the clinician.
JCO Oncol Pract. 20:1441–1451. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Lișcu HD, Verga N, Atasiei DI, Badiu DC,
Dumitru AV, Ultimescu F, Pavel C, Stefan RE, Manole DC and Ionescu
AI: Biomarkers in colorectal cancer: Actual and future
perspectives. Int J Mol Sci. 25:115352024. View Article : Google Scholar :
|
|
195
|
Marcus L, Fashoyin-Aje LA, Donoghue M,
Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR,
Beaver JA, et al: FDA approval summary: Pembrolizumab for the
treatment of tumor mutational burden-high solid tumors. Clin Cancer
Res. 27:4685–4689. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Puccini A, Seeber A and Berger MD:
Biomarkers in metastatic colorectal cancer: Status quo and future
perspective. Cancers (Basel). 14:48282022. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Sunshine J and Taube JM: PD-1/PD-L1
inhibitors. Curr Opin Pharmacol. 23:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Matsuhashi N, Yamada T, Nagasaka T,
Kataoka K, Sakamoto K, Koda K, Hiramatsu K, Matsuoka H, Kuramochi
H, Ishida H, et al: Impact of RAS and BRAF heterogeneity on the
efficacy of EGFR blockade in patients with metastatic colorectal
cancer. J Clin Oncol. 43(4 Suppl): S2552025. View Article : Google Scholar
|
|
200
|
Ogunwobi OO, Mahmood F and Akingboye A:
Biomarkers in colorectal cancer: Current research and future
prospects. Int J Mol Sci. 21:53112020. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
De Mattia E, Polesel J, Mezzalira S,
Palazzari E, Pollesel S, Toffoli G and Cecchin E: Predictive and
prognostic value of oncogene mutations and microsatellite
instability in locally-advanced rectal cancer treated with
neoadjuvant radiation-based therapy: A systematic review and
meta-analysis. Cancers (Basel). 15:14692023. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Santollani L, Maiorino L, Zhang YJ,
Palmeri JR, Stinson JA, Duhamel LR, Qureshi K, Suggs JR, Porth OT,
Pinney W III, et al: Local delivery of cell surface-targeted
immunocytokines programs systemic antitumor immunity. Nat Immunol.
25:1820–1829. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zhang Y, Shi X, Shen Y, Dong X, He R, Chen
G, Zhang Y, Tan H and Zhang K: Nanoengineering-armed oncolytic
viruses drive antitumor response: Progress and challenges. MedComm.
5:e7552024. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Hwang SR, Chakraborty K, An JM, Mondal J,
Yoon HY and Lee Y: Pharmaceutical aspects of nanocarriers for smart
anticancer therapy. Pharmaceutics. 13:18752021. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Choi JW, Nam JP, Nam K, Lee YS, Yun CO and
Kim SW: Oncolytic adenovirus coated with multidegradable
bioreducible core-cross-linked polyethylenimine for cancer gene
therapy. Biomacromolecules. 16:2132–2143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Yang Y, Liu Q, Wang M, Li L, Yu Y, Pan M,
Hu D, Chu B, Qu Y and Qian Z: Genetically programmable cell
membrane-camouflaged nanoparticles for targeted combination therapy
of colorectal cancer. Signal Transduct Target Ther. 9:1582024.
View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Fang C, Xiao G, Wang T, Song L, Peng B, Xu
B and Zhang K: Emerging nano-/biotechnology drives oncolytic
virus-activated and combined cancer immunotherapy. Research (Wash D
C). 6:01082023.PubMed/NCBI
|
|
208
|
Zhou F, Zhu H and Fu C: Editorial:
Clinical therapeutic development against cancers resistant to
targeted therapies. Front Pharmacol. 12:8168962022. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Kaufman HL, Kohlhapp FJ and Zloza A:
Erratum: Oncolytic viruses: A new class of immunotherapy drugs. Nat
Rev Drug Discov. 15:6602016. View Article : Google Scholar
|
|
210
|
Lichty BD, Breitbach CJ, Stojdl DF and
Bell JC: Going viral with cancer immunotherapy. Nat Rev Cancer.
14:559–567. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Lawler SE, Speranza MC, Cho CF and Chiocca
EA: Oncolytic viruses in cancer treatment: A review. JAMA Oncol.
3:841–849. 2017. View Article : Google Scholar
|
|
212
|
Li X and Cheng Z: Oncolytic viruses in
cancer immunotherapy. Adv Ther. 7:23004452024. View Article : Google Scholar
|
|
213
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Lv D, Fei Y, Chen H, Wang J, Han W, Cui B,
Feng Y, Zhang P and Chen J: Crosstalk between T lymphocyte and
extracellular matrix in tumor microenvironment. Front Immunol.
15:13407022024. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Fox CR and Parks GD: Histone deacetylase
inhibitors enhance cell killing and block interferon-beta synthesis
elicited by infection with an oncolytic parainfluenza virus.
Viruses. 11:4312019. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Jennings VA, Scott GB, Rose AMS, Scott KJ,
Migneco G, Keller B, Reilly K, Donnelly O, Peach H, Dewar D, et al:
Potentiating oncolytic virus-induced immune-mediated tumor cell
killing using histone deacetylase inhibition. Mol Ther.
27:1139–1152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Roulstone V, Pedersen M, Kyula J,
Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E,
Coffey M, Marais R, et al: BRAF- and MEK-targeted small molecule
inhibitors exert enhanced antimelanoma effects in combination with
oncolytic reovirus through ER stress. Mol Ther. 23:931–942. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
218
|
De Henau O, Rausch M, Winkler D, Campesato
LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et
al: Overcoming resistance to checkpoint blockade therapy by
targeting PI3Kγ in myeloid cells. Nature. 539:443–447. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Choi HJ, Chung TW, Kang SK, Lee YC, Ko JH,
Kim JG and Kim CH: Ganglioside GM3 modulates tumor suppressor
PTEN-mediated cell cycle progression-transcriptional induction of
p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Glycobiology. 16:573–583. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Kazanets A, Shorstova T, Hilmi K, Marques
M and Witcher M: Epigenetic silencing of tumor suppressor genes:
Paradigms, puzzles, and potential. Biochim Biophys Acta.
1865:275–288. 2016.PubMed/NCBI
|
|
221
|
Wallace BD, Wang H, Lane KT, Scott JE,
Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S and Redinbo
MR: Alleviating cancer drug toxicity by inhibiting a bacterial
enzyme. Science. 330:831–835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Jung G, Hernández-Illán E, Moreira L,
Balaguer F and Goel A: Epigenetics of colorectal cancer: Biomarker
and therapeutic potential. Nat Rev Gastroenterol Hepatol.
17:111–130. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Kaur M, Frahm F, Lu Y, Ascha MS, Guadamuz
JS, Dotan E, Gottesman AS, Leybovich BC, Sondhi A, Zhao Y, et al:
Broadening eligibility criteria and diversity among patients for
cancer clinical trials. NEJM Evid. 3:EVIDoa23002362024. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Veen T, Kanani A, Lea D and Søreide K:
Clinical trials of neoadjuvant immune checkpoint inhibitors for
early-stage operable colon and rectal cancer. Cancer Immunol
Immunother. 72:3135–3147. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Li C, Ferro A, Mhatre SK, Lu D, Lawrance
M, Li X, Li S, Allen S, Desai J, Fakih M, et al: Hybrid-control arm
construction using historical trial data for an early-phase,
randomized controlled trial in metastatic colorectal cancer. Commun
Med (Lond). 2:902022. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Qi Z, Gu J, Qu L, Shi X, He Z, Sun J, Tan
L and Sun M: Advancements of engineered live oncolytic
biotherapeutics (microbe/virus/cells): Preclinical research and
clinical progress. J Control Release. 375:209–235. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Xu Z, Li W, Dong X, Chen Y, Zhang D, Wang
J, Zhou L and He G: Precision medicine in colorectal cancer:
Leveraging multi-omics, spatial omics, and artificial intelligence.
Clin Chim Acta. 559:1196862024. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Cornish AJ, Gruber AJ, Kinnersley B, Chubb
D, Frangou A, Caravagna G, Noyvert B, Lakatos E, Wood HM, Thorn S,
et al: The genomic landscape of 2,023 colorectal cancers. Nature.
633:127–136. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Gujar S, Pol JG, Kim Y, Lee PW and Kroemer
G: Antitumor benefits of antiviral immunity: An underappreciated
aspect of oncolytic virotherapies. Trends Immunol. 39:209–221.
2018. View Article : Google Scholar
|
|
230
|
Su Y, Su C and Qin L: Current landscape
and perspective of oncolytic viruses and their combination
therapies. Transl Oncol. 25:1015302022. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Bi Y, Sun L, Gao D, Ding C, Li Z, Li Y,
Cun W and Li Q: High-efficiency targeted editing of large viral
genomes by RNA-guided nucleases. PLoS Pathog. 10:e10040902014.
View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Hsu PD, Lander ES and Zhang F: Development
and applications of CRISPR-Cas9 for genome engineering. Cell.
157:1262–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Cornall AM, Phillips S, Cummins E, Garland
SM and Tabrizi SN: In vitro assessment of the effect of
vaccine-targeted human papillomavirus (HPV) depletion on detection
of non-vaccine HPV types: Implications for post-vaccine
surveillance studies. J Virol Methods. 214:10–14. 2015. View Article : Google Scholar
|
|
234
|
Monge C, Xie C, Myojin Y, Coffman K,
Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, et al:
Phase I/II study of PexaVec in combination with immune checkpoint
inhibition in refractory metastatic colorectal cancer. J Immunother
Cancer. 11:e0056402023. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Zhang B, Huang J, Tang J, Hu S, Luo S, Luo
Z, Zhou F, Tan S, Ying J, Chang Q, et al: Intratumoral OH2, an
oncolytic herpes simplex virus 2, in patients with advanced solid
tumors: A multicenter, phase I/II clinical trial. J Immunother
Cancer. 9:e0022242021. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Zhang L, Pakmehr SA, Shahhosseini R,
Hariri M, Fakhrioliaei A, Karkon Shayan F, Xiang W and Karkon
Shayan S: Oncolytic viruses improve cancer immunotherapy by
reprogramming solid tumor microenvironment. Med Oncol. 41:82023.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Fakih M, Raghav KPS, Chang DZ, Larson T,
Cohn AL, Huyck TK, Cosgrove D, Fiorillo JA, Tam R, D'Adamo D, et
al: Regorafenib plus nivolumab in patients with mismatch
repair-proficient/microsatellite stable metastatic colorectal
cancer: A single-arm, open-label, multicentre phase 2 study.
EClinicalMedicine. 58:1019172023. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Wang N, Wang J, Zhang Z, Cao H, Yan W, Chu
Y, Chard Dunmall LS and Wang Y: A novel vaccinia virus enhances
anti-tumor efficacy and promotes a long-term anti-tumor response in
a murine model of colorectal cancer. Mol Ther Oncolytics. 20:71–81.
2020. View Article : Google Scholar
|
|
239
|
Chen L, Chen H, Ye J, Ge Y, Wang H, Dai E,
Ren J, Liu W, Ma C, Ju S, et al: Intratumoral expression of
interleukin 23 variants using oncolytic vaccinia virus elicit
potent antitumor effects on multiple tumor models via tumor
microenvironment modulation. Theranostics. 11:6668–6681. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Deng L, Yang X, Fan J, Ding Y, Peng Y, Xu
D, Huang B and Hu Z: IL-24-Armed oncolytic vaccinia virus exerts
potent antitumor effects via multiple pathways in colorectal
cancer. Oncol Res. 28:579–590. 2021. View Article : Google Scholar :
|
|
241
|
Li J, O'Malley M, Sampath P, Kalinski P,
Bartlett DL and Thorne SH: Expression of CCL19 from oncolytic
vaccinia enhances immunotherapeutic potential while maintaining
oncolytic activity. Neoplasia. 14:1115–1121. 2012. View Article : Google Scholar
|
|
242
|
Flanagan K, Glover RT, Hörig H, Yang W and
Kaufman HL: Local delivery of recombinant vaccinia virus expressing
secondary lymphoid chemokine (SLC) results in a CD4 T-cell
dependent antitumor response. Vaccine. 22:2894–2903. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Bereta M, Bereta J, Park J, Medina F, Kwak
H and Kaufman HL: Immune properties of recombinant vaccinia virus
encoding CD154 (CD40L) are determined by expression of virally
encoded CD40L and the presence of CD40L protein in viral particles.
Cancer Gene Ther. 11:808–818. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Warner SG, Kim SI, Chaurasiya S, O'Leary
MP, Lu J, Sivanandam V, Woo Y, Chen NG and Fong Y: A novel chimeric
poxvirus encoding hNIS Is tumor-tropic, imageable, and synergistic
with radioiodine to sustain colon cancer regression. Mol Ther
Oncolytics. 13:82–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Xing M, Wang X, Chi Y and Zhou D: Gene
therapy for colorectal cancer using adenovirus-mediated full-length
antibody, cetuximab. Oncotarget. 7:28262–28272. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Rong Y, Ning Y, Zhu J, Feng P, Zhu W, Zhao
X, Xiong Z, Ruan C, Jin J, Wang H, et al: Oncolytic adenovirus
encoding decorin and CD40 ligand inhibits tumor growth and liver
metastasis via immune activation in murine colorectal tumor model.
Mol Biomed. 5:392024. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Nie ZL, Pan YQ, He BS, Gu L, Chen LP, Li
R, Xu YQ, Gao TY, Song GQ, Hoffman AR, et al: Gene therapy for
colorectal cancer by an oncolytic adenovirus that targets loss of
the insulin-like growth factor 2 imprinting system. Mol Cancer.
11:862012. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Hecht JR, Raman SS, Chan A, Kalinsky K,
Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A,
et al: Phase Ib study of talimogene laherparepvec in combination
with atezolizumab in patients with triple negative breast cancer
and colorectal cancer with liver metastases. ESMO Open.
8:1008842023. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Tian L, Liu T, Jiang S, Cao Y, Kang K, Su
H, Ren G, Wang Z, Xiao W and Li D: Oncolytic Newcastle disease
virus expressing the co-stimulator OX40L as immunopotentiator for
colorectal cancer therapy. Gene Ther. 30:64–74. 2023. View Article : Google Scholar
|
|
250
|
Vigil A, Park MS, Martinez O, Chua MA,
Xiao S, Cros JF, Martínez-Sobrido L, Woo SL and García-Sastre A:
Use of reverse genetics to enhance the oncolytic properties of
Newcastle disease virus. Cancer Res. 67:8285–8292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Li X, Wang Z, Zhang S, Yao Q, Chen W and
Liu F: Ruxolitinib induces apoptosis of human colorectal cancer
cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. Oncol Lett.
21:3522021. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Ghonime MG and Cassady KA: Combination
therapy using ruxolitinib and oncolytic HSV renders resistant
MPNSTs susceptible to virotherapy. Cancer Immunol Res. 6:1499–1510.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Hong YS, Hong SW, Kim SM, Jin DH, Shin JS,
Yoon DH, Kim KP, Lee JL, Heo DS, Lee JS and Kim TW: Bortezomib
induces G2-M arrest in human colon cancer cells through
ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol. 41:76–82.
2012.PubMed/NCBI
|
|
254
|
Kim Y, Lee J, Lee D and Othmer HG:
Synergistic effects of bortezomib-OV therapy and anti-invasive
strategies in glioblastoma: A mathematical model. Cancers (Basel).
11:2152019. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Li X, Hu W, Shen J, Li M and Gong W:
Targeting proteasome enhances anticancer activity of oncolytic
HSV-1 in colorectal cancer. Virology. 578:13–21. 2023. View Article : Google Scholar
|
|
256
|
Dinu IM, Mihăilă M, Diculescu MM, Croitoru
VM, Turcu-Stiolica A, Bogdan D, Miron MI, Lungulescu CV,
Alexandrescu ST, Dumitrașcu T, et al: Bevacizumab treatment for
metastatic colorectal cancer in real-world clinical practice.
Medicina (Kaunas). 59:3502023. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Saoudi González N, Ros J, Baraibar I,
Salvà F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J and
Élez E: Cetuximab as a key partner in personalized targeted therapy
for metastatic colorectal cancer. Cancers (Basel). 16:4122024.
View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Yang S, Li X, Guan W, Qian M, Yao Z, Yin X
and Zhao H: NVP-BKM120 inhibits colon cancer growth via
FoxO3a-dependent PUMA induction. Oncotarget. 8:83052–83062. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
259
|
Wang L, Ning J, Wakimoto H, Wu S, Wu CL,
Humphrey MR, Rabkin SD and Martuza RL: Oncolytic herpes simplex
virus and PI3K inhibitor BKM120 synergize to promote killing of
prostate cancer stem-like cells. Mol Ther Oncolytics. 13:58–66.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
260
|
Soltantoyeh T, Akbari B, Shahosseini Z,
Mirzaei HR and Hadjati J: Simultaneous targeting of Tim3 and A2a
receptors modulates MSLN-CAR T cell antitumor function in a human
cervical tumor xenograft model. Front Immunol. 15:13629042024.
View Article : Google Scholar : PubMed/NCBI
|
|
261
|
Chin K, Chand VK and Nuyten DSA: Avelumab:
Clinical trial innovation and collaboration to advance anti-PD-L1
immunotherapy. Ann Oncol. 28:1658–1666. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
262
|
Redman JM, O'Sullivan Coyne G, Reed CT,
Madan RA, Strauss J, Steinberg SJ, Marté J, Cordes L, Heery C and
Gulley JL: Avelumab in patients with metastatic colorectal cancer.
Oncologist. 28:823–e804. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
263
|
Español-Rego M, Fernández-Martos C, Elez
E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid
J, Cabezón R, et al: A phase I-II multicenter trial with Avelumab
plus autologous dendritic cell vaccine in pre-treated mismatch
repair-proficient (MSS) metastatic colorectal cancer patients;
GEMCAD 1602 study. Cancer Immunol Immunother. 72:827–840. 2023.
View Article : Google Scholar :
|
|
264
|
Zhu WM and Middleton MR: Combination
therapies for the optimisation of bispecific T-cell engagers in
cancer treatment. Immunother Adv. 3:ltad0132023. View Article : Google Scholar : PubMed/NCBI
|
|
265
|
Heidbuechel JPW and Engeland CE: Oncolytic
viruses encoding bispecific T cell engagers: A blueprint for
emerging immunovirotherapies. J Hematol Oncol. 14:632021.
View Article : Google Scholar : PubMed/NCBI
|
|
266
|
Puca E, Schmitt-Koopmann C, Furter M,
Murer P, Probst P, Dihr M, Bajic D and Neri D: The targeted
delivery of interleukin-12 to the carcinoembryonic antigen
increases the intratumoral density of NK and CD8+ T cell
in an immunocompetent mouse model of colorectal cancer. J
Gastrointest Oncol. 11:803–811. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
267
|
Li Q, Oduro PK, Guo R, Li R, Leng L, Kong
X, Wang Q and Yang L: Oncolytic viruses: Immunotherapy drugs for
gastrointestinal malignant tumors. Front Cell Infect Microbiol.
12:9215342022. View Article : Google Scholar : PubMed/NCBI
|
|
268
|
Sumransub N, Vantanasiri K, Prakash A and
Lou E: Advances and new frontiers for immunotherapy in colorectal
cancer: Setting the stage for neoadjuvant success? Mol Ther
Oncolytics. 22:1–12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
269
|
Yoo SY, Bang SY, Jeong SN, Kang DH and Heo
J: A cancer-favoring oncolytic vaccinia virus shows enhanced
suppression of stem-cell like colon cancer. Oncotarget.
7:16479–16489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
270
|
Shebbo S, Binothman N, Darwaish M, Niaz
HA, Abdulal RH, Borjac J, Hashem AM and Mahmoud AB: Redefining the
battle against colorectal cancer: A comprehensive review of
emerging immunotherapies and their clinical efficacy. Front
Immunol. 15:13502082024. View Article : Google Scholar : PubMed/NCBI
|
